peptide p60 Search Results


94
MedChemExpress peptide p60
Peptide P60, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+p60/Peptide+P60/pm41896541-69-0-5
Average 94 stars, based on 1 article reviews
peptide p60 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
ProSci Incorporated anti p62
FIG. 3. Cdk inhibition down-regulates <t>SQSTM1/p62</t> but fails to affect LC3 processing during
Anti P62, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+p60/SQSTM1+Peptide/10__1128_slash_mcb__01383___13-71-15-24
Average 90 stars, based on 1 article reviews
anti p62 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sino Biological tyr
FIG. 3. Cdk inhibition down-regulates <t>SQSTM1/p62</t> but fails to affect LC3 processing during
Tyr, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+p60/Poly+(6%3A2%3A5%3A1+Ala%2CGlu%2CLys%2CTyr)+Peptide/pmc07401407-82-4-10
Average 90 stars, based on 1 article reviews
tyr - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Abbiotec Inc treg inhibitor (peptide p60)
PGRN exerts its inhibitory effect by inducing the conversion of CD4 + T lymphocytes to iTregs <t>via</t> <t>TGF-</t> β . CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 20 μ M of TGF- β inhibitor for 5 days (a). CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 25 μ g/ml of <t>Treg</t> inhibitor for 5 days (b). Treated cells were collected and divided into two; one lot was stained for iTregs and the other was analyzed by cell proliferation assay. Flow cytometry was performed to determine iTregs and the proportion of iTregs. Upper panels in show the percentage of CD4 + T lymphocytes incorporated with EdU. Lower panels show the percentage of CD4 + Foxp3 + iTreg ((a) and (b)). Data are presented as means ± standard deviations of three experiments performed in triplicate. ∗∗ p < 0.01, ∗∗∗ p < 0.001, or ns (not significant). Similar results were obtained in three independent experiments.
Treg Inhibitor (Peptide P60), supplied by Abbiotec Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+p60/peptide+p60/pmc05282443-37-13-17
Average 90 stars, based on 1 article reviews
treg inhibitor (peptide p60) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Oryza Oil Fat Chemical Co Ltd oryza peptide p60
PGRN exerts its inhibitory effect by inducing the conversion of CD4 + T lymphocytes to iTregs <t>via</t> <t>TGF-</t> β . CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 20 μ M of TGF- β inhibitor for 5 days (a). CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 25 μ g/ml of <t>Treg</t> inhibitor for 5 days (b). Treated cells were collected and divided into two; one lot was stained for iTregs and the other was analyzed by cell proliferation assay. Flow cytometry was performed to determine iTregs and the proportion of iTregs. Upper panels in show the percentage of CD4 + T lymphocytes incorporated with EdU. Lower panels show the percentage of CD4 + Foxp3 + iTreg ((a) and (b)). Data are presented as means ± standard deviations of three experiments performed in triplicate. ∗∗ p < 0.01, ∗∗∗ p < 0.001, or ns (not significant). Similar results were obtained in three independent experiments.
Oryza Peptide P60, supplied by Oryza Oil Fat Chemical Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+p60/oryza+peptide+p60/us11382911-30-30-35
Average 90 stars, based on 1 article reviews
oryza peptide p60 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MultiSynTech gmbh p60
PGRN exerts its inhibitory effect by inducing the conversion of CD4 + T lymphocytes to iTregs <t>via</t> <t>TGF-</t> β . CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 20 μ M of TGF- β inhibitor for 5 days (a). CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 25 μ g/ml of <t>Treg</t> inhibitor for 5 days (b). Treated cells were collected and divided into two; one lot was stained for iTregs and the other was analyzed by cell proliferation assay. Flow cytometry was performed to determine iTregs and the proportion of iTregs. Upper panels in show the percentage of CD4 + T lymphocytes incorporated with EdU. Lower panels show the percentage of CD4 + Foxp3 + iTreg ((a) and (b)). Data are presented as means ± standard deviations of three experiments performed in triplicate. ∗∗ p < 0.01, ∗∗∗ p < 0.001, or ns (not significant). Similar results were obtained in three independent experiments.
P60, supplied by MultiSynTech gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+p60/p60+peptide/us07803756-297-16-34
Average 90 stars, based on 1 article reviews
p60 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
SynPep Corporation synthetic p60 c-src peptide (521-533) thr-ser-thr-glu-pro-gln-tyr-gln-pro-gly-glu-asn-leu-cooh
PGRN exerts its inhibitory effect by inducing the conversion of CD4 + T lymphocytes to iTregs <t>via</t> <t>TGF-</t> β . CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 20 μ M of TGF- β inhibitor for 5 days (a). CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 25 μ g/ml of <t>Treg</t> inhibitor for 5 days (b). Treated cells were collected and divided into two; one lot was stained for iTregs and the other was analyzed by cell proliferation assay. Flow cytometry was performed to determine iTregs and the proportion of iTregs. Upper panels in show the percentage of CD4 + T lymphocytes incorporated with EdU. Lower panels show the percentage of CD4 + Foxp3 + iTreg ((a) and (b)). Data are presented as means ± standard deviations of three experiments performed in triplicate. ∗∗ p < 0.01, ∗∗∗ p < 0.001, or ns (not significant). Similar results were obtained in three independent experiments.
Synthetic P60 C Src Peptide (521 533) Thr Ser Thr Glu Pro Gln Tyr Gln Pro Gly Glu Asn Leu Cooh, supplied by SynPep Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+p60/synthetic+p60+c+src+peptide++521+533++thr+ser+thr+glu+pro+gln+tyr+gln+pro+gly+glu+asn+leu+cooh/us08945932-520-7-26
Average 90 stars, based on 1 article reviews
synthetic p60 c-src peptide (521-533) thr-ser-thr-glu-pro-gln-tyr-gln-pro-gly-glu-asn-leu-cooh - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Neo MPS Inc peptide p60 (rdfqsfrkmwpffam)
PGRN exerts its inhibitory effect by inducing the conversion of CD4 + T lymphocytes to iTregs <t>via</t> <t>TGF-</t> β . CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 20 μ M of TGF- β inhibitor for 5 days (a). CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 25 μ g/ml of <t>Treg</t> inhibitor for 5 days (b). Treated cells were collected and divided into two; one lot was stained for iTregs and the other was analyzed by cell proliferation assay. Flow cytometry was performed to determine iTregs and the proportion of iTregs. Upper panels in show the percentage of CD4 + T lymphocytes incorporated with EdU. Lower panels show the percentage of CD4 + Foxp3 + iTreg ((a) and (b)). Data are presented as means ± standard deviations of three experiments performed in triplicate. ∗∗ p < 0.01, ∗∗∗ p < 0.001, or ns (not significant). Similar results were obtained in three independent experiments.
Peptide P60 (Rdfqsfrkmwpffam), supplied by Neo MPS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+p60/peptide+p60++rdfqsfrkmwpffam+/pm20870946-53-0-30
Average 90 stars, based on 1 article reviews
peptide p60 (rdfqsfrkmwpffam) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
OctoPlus Inc ll-37 derived antimicrobial peptide p60.4-ac
PGRN exerts its inhibitory effect by inducing the conversion of CD4 + T lymphocytes to iTregs <t>via</t> <t>TGF-</t> β . CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 20 μ M of TGF- β inhibitor for 5 days (a). CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 25 μ g/ml of <t>Treg</t> inhibitor for 5 days (b). Treated cells were collected and divided into two; one lot was stained for iTregs and the other was analyzed by cell proliferation assay. Flow cytometry was performed to determine iTregs and the proportion of iTregs. Upper panels in show the percentage of CD4 + T lymphocytes incorporated with EdU. Lower panels show the percentage of CD4 + Foxp3 + iTreg ((a) and (b)). Data are presented as means ± standard deviations of three experiments performed in triplicate. ∗∗ p < 0.01, ∗∗∗ p < 0.001, or ns (not significant). Similar results were obtained in three independent experiments.
Ll 37 Derived Antimicrobial Peptide P60.4 Ac, supplied by OctoPlus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+p60/ll+37+derived+antimicrobial+peptide+p60+4+ac/10__1097_slash_mlg__0b013e31816422d7-26-131-154
Average 90 stars, based on 1 article reviews
ll-37 derived antimicrobial peptide p60.4-ac - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Alta Bioscience rdfqsfrkmwpffam p60-peptide with the covalent bound sulfo-smcc
PGRN exerts its inhibitory effect by inducing the conversion of CD4 + T lymphocytes to iTregs <t>via</t> <t>TGF-</t> β . CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 20 μ M of TGF- β inhibitor for 5 days (a). CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 25 μ g/ml of <t>Treg</t> inhibitor for 5 days (b). Treated cells were collected and divided into two; one lot was stained for iTregs and the other was analyzed by cell proliferation assay. Flow cytometry was performed to determine iTregs and the proportion of iTregs. Upper panels in show the percentage of CD4 + T lymphocytes incorporated with EdU. Lower panels show the percentage of CD4 + Foxp3 + iTreg ((a) and (b)). Data are presented as means ± standard deviations of three experiments performed in triplicate. ∗∗ p < 0.01, ∗∗∗ p < 0.001, or ns (not significant). Similar results were obtained in three independent experiments.
Rdfqsfrkmwpffam P60 Peptide With The Covalent Bound Sulfo Smcc, supplied by Alta Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+p60/rdfqsfrkmwpffam+p60+peptide+with+the+covalent+bound+sulfo+smcc/pm26999456-139-5-13
Average 90 stars, based on 1 article reviews
rdfqsfrkmwpffam p60-peptide with the covalent bound sulfo-smcc - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier


Image Search Results


FIG. 3. Cdk inhibition down-regulates SQSTM1/p62 but fails to affect LC3 processing during

Journal: Molecular and Cellular Biology

Article Title: Targeting SQSTM1/p62 Induces Cargo Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik

doi: 10.1128/mcb.01383-13

Figure Lengend Snippet: FIG. 3. Cdk inhibition down-regulates SQSTM1/p62 but fails to affect LC3 processing during

Article Snippet: The SDS-insoluble aggregates trapped on the filter were probed with anti-ubiquitin (Cell Signaling, Beverly, MA), anti-p62 (Santa Cruz Biotech, Santa Cruz, CA), or anti-Bik (ProSci, Poway, CA), respectively.

Techniques: Inhibition

FIG. 4. SQSTM1/p62 down-regulation results in cargo loading failure and inefficient autophagy.

Journal: Molecular and Cellular Biology

Article Title: Targeting SQSTM1/p62 Induces Cargo Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik

doi: 10.1128/mcb.01383-13

Figure Lengend Snippet: FIG. 4. SQSTM1/p62 down-regulation results in cargo loading failure and inefficient autophagy.

Article Snippet: The SDS-insoluble aggregates trapped on the filter were probed with anti-ubiquitin (Cell Signaling, Beverly, MA), anti-p62 (Santa Cruz Biotech, Santa Cruz, CA), or anti-Bik (ProSci, Poway, CA), respectively.

Techniques:

FIG. 5. Expression of SQSTM1/p62 diminishes the increased lethality of BH3-mimetics in p62-

Journal: Molecular and Cellular Biology

Article Title: Targeting SQSTM1/p62 Induces Cargo Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik

doi: 10.1128/mcb.01383-13

Figure Lengend Snippet: FIG. 5. Expression of SQSTM1/p62 diminishes the increased lethality of BH3-mimetics in p62-

Article Snippet: The SDS-insoluble aggregates trapped on the filter were probed with anti-ubiquitin (Cell Signaling, Beverly, MA), anti-p62 (Santa Cruz Biotech, Santa Cruz, CA), or anti-Bik (ProSci, Poway, CA), respectively.

Techniques: Expressing

FIG. 9. A mechanistic model of SQSTM1/p62 and NBK/Bik acting as novel molecular switches

Journal: Molecular and Cellular Biology

Article Title: Targeting SQSTM1/p62 Induces Cargo Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik

doi: 10.1128/mcb.01383-13

Figure Lengend Snippet: FIG. 9. A mechanistic model of SQSTM1/p62 and NBK/Bik acting as novel molecular switches

Article Snippet: The SDS-insoluble aggregates trapped on the filter were probed with anti-ubiquitin (Cell Signaling, Beverly, MA), anti-p62 (Santa Cruz Biotech, Santa Cruz, CA), or anti-Bik (ProSci, Poway, CA), respectively.

Techniques:

PGRN exerts its inhibitory effect by inducing the conversion of CD4 + T lymphocytes to iTregs via TGF- β . CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 20 μ M of TGF- β inhibitor for 5 days (a). CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 25 μ g/ml of Treg inhibitor for 5 days (b). Treated cells were collected and divided into two; one lot was stained for iTregs and the other was analyzed by cell proliferation assay. Flow cytometry was performed to determine iTregs and the proportion of iTregs. Upper panels in show the percentage of CD4 + T lymphocytes incorporated with EdU. Lower panels show the percentage of CD4 + Foxp3 + iTreg ((a) and (b)). Data are presented as means ± standard deviations of three experiments performed in triplicate. ∗∗ p < 0.01, ∗∗∗ p < 0.001, or ns (not significant). Similar results were obtained in three independent experiments.

Journal: Mediators of Inflammation

Article Title: Progranulin Inhibits Human T Lymphocyte Proliferation by Inducing the Formation of Regulatory T Lymphocytes

doi: 10.1155/2017/7682083

Figure Lengend Snippet: PGRN exerts its inhibitory effect by inducing the conversion of CD4 + T lymphocytes to iTregs via TGF- β . CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 20 μ M of TGF- β inhibitor for 5 days (a). CD4 + T lymphocytes were stimulated with PHA and incubated with PGRN in the presence or absence of 1, 10, and 25 μ g/ml of Treg inhibitor for 5 days (b). Treated cells were collected and divided into two; one lot was stained for iTregs and the other was analyzed by cell proliferation assay. Flow cytometry was performed to determine iTregs and the proportion of iTregs. Upper panels in show the percentage of CD4 + T lymphocytes incorporated with EdU. Lower panels show the percentage of CD4 + Foxp3 + iTreg ((a) and (b)). Data are presented as means ± standard deviations of three experiments performed in triplicate. ∗∗ p < 0.01, ∗∗∗ p < 0.001, or ns (not significant). Similar results were obtained in three independent experiments.

Article Snippet: Human TGF- β RI Kinase Inhibitor VI (SB431542, Selleckchem, Houston, TX, USA) or Treg inhibitor (Peptide P60, Abbiotec, San Diego, CA, USA) was used to block the formation of iTregs, and recombinant human TGF- β 1 protein (R&D System, Minneapolis, MN, USA) was used to induce the formation of iTregs.

Techniques: Incubation, Staining, Proliferation Assay, Flow Cytometry